219 related articles for article (PubMed ID: 23462811)
1. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease.
Noelker C; Morel L; Lescot T; Osterloh A; Alvarez-Fischer D; Breloer M; Henze C; Depboylu C; Skrzydelski D; Michel PP; Dodel RC; Lu L; Hirsch EC; Hunot S; Hartmann A
Sci Rep; 2013; 3():1393. PubMed ID: 23462811
[TBL] [Abstract][Full Text] [Related]
2. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease.
Shao QH; Chen Y; Li FF; Wang S; Zhang XL; Yuan YH; Chen NH
Acta Pharmacol Sin; 2019 Dec; 40(12):1503-1512. PubMed ID: 31388087
[TBL] [Abstract][Full Text] [Related]
3. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
[TBL] [Abstract][Full Text] [Related]
4. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
5. TLR4 signaling mediates AP-1 activation in an MPTP-induced mouse model of Parkinson's disease.
Zhao XD; Wang FX; Cao WF; Zhang YH; Li Y
Int Immunopharmacol; 2016 Mar; 32():96-102. PubMed ID: 26803521
[TBL] [Abstract][Full Text] [Related]
6. Role of melatonin in TLR4-mediated inflammatory pathway in the MTPT-induced mouse model.
Yildirim S; Ozkan A; Aytac G; Agar A; Tanriover G
Neurotoxicology; 2022 Jan; 88():168-177. PubMed ID: 34808223
[TBL] [Abstract][Full Text] [Related]
7. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
8. Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Kuroiwa H; Yokoyama H; Kimoto H; Kato H; Araki T
Metab Brain Dis; 2010 Jun; 25(2):177-83. PubMed ID: 20431930
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes of activated AHR in microglia and astrocytes in the substantia nigra-striatum system in an MPTP-induced Parkinson's disease mouse model.
Zhou Y; Zhao WJ; Quan W; Qiao CM; Cui C; Hong H; Shi Y; Niu GY; Zhao LP; Shen YQ
Brain Res Bull; 2021 Nov; 176():174-183. PubMed ID: 34478811
[TBL] [Abstract][Full Text] [Related]
10. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
11. Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion.
Oeckl P; Scheffold A; Lechel A; Rudolph KL; Ferger B
Neuroreport; 2014 Mar; 25(5):335-9. PubMed ID: 24525820
[TBL] [Abstract][Full Text] [Related]
12. Toll Like Receptor 4 Affects the Cerebral Biochemical Changes Induced by MPTP Treatment.
Conte C; Roscini L; Sardella R; Mariucci G; Scorzoni S; Beccari T; Corte L
Neurochem Res; 2017 Feb; 42(2):493-500. PubMed ID: 28108849
[TBL] [Abstract][Full Text] [Related]
13. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.
Pattarini R; Smeyne RJ; Morgan JI
Neuroscience; 2007 Mar; 145(2):654-68. PubMed ID: 17258864
[TBL] [Abstract][Full Text] [Related]
14. MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Viaggi C; Vaglini F; Pardini C; Caramelli A; Corsini GU
Neuropharmacology; 2009 Jun; 56(8):1075-81. PubMed ID: 19298832
[TBL] [Abstract][Full Text] [Related]
15. Behavioral, Biochemical and Molecular Characterization of a Parkinson's Disease Mouse Model Using the Neurotoxin 2'-CH
Herlinger AL; Almeida AR; Presti-Silva SM; Pereira EV; Andrich F; Pires RGW; Martins-Silva C
Neuromolecular Med; 2018 Mar; 20(1):73-82. PubMed ID: 29332269
[TBL] [Abstract][Full Text] [Related]
16. DAP12 and CD11b contribute to the microglial-induced death of dopaminergic neurons in vitro but not in vivo in the MPTP mouse model of Parkinson's disease.
Kinugawa K; Monnet Y; Béchade C; Alvarez-Fischer D; Hirsch EC; Bessis A; Hunot S
J Neuroinflammation; 2013 Jul; 10():82. PubMed ID: 23844828
[TBL] [Abstract][Full Text] [Related]
17. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Schlüter OM; Fornai F; Alessandrí MG; Takamori S; Geppert M; Jahn R; Südhof TC
Neuroscience; 2003; 118(4):985-1002. PubMed ID: 12732244
[TBL] [Abstract][Full Text] [Related]
18. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.
Drouin-Ouellet J; Gibrat C; Bousquet M; Calon F; Kriz J; Cicchetti F
J Neuroinflammation; 2011 Oct; 8():137. PubMed ID: 21989292
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
[TBL] [Abstract][Full Text] [Related]
20. Asparagine endopeptidase deletion ameliorates cognitive impairments by inhibiting proinflammatory microglial activation in MPTP mouse model of Parkinson disease.
Gao J; Zhang W; Chai X; Tan X; Yang Z
Brain Res Bull; 2022 Jan; 178():120-130. PubMed ID: 34838642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
